Buscar
01/09/2025
Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl, M, Langley, RG, Strober, B, Thaçi, D, Armstrong, A, Gordon, KB, Puig, L, Davies, O, Peterson, L, Davis, L, Warren, RB. Bimekizumab achievement of 'super response' using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).
01/07/2025
Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study
Ceravalls, J, Giménez-Arnau, AM, Exposito-Serrano, V, Chico, NF, Moya, AL, Bielsa, I, Ribó, P, Mascaró-Hereza, B, Bonfill-Orti, M, Spertino, J, Serra, E, Baliu-Piqué, C, Melé-Ninot, G. Redefining Omalizumab Discontinuation in Chronic Spontaneous Urticaria: The Value of Optimization and Predictive Factors of Relapse. A 52-Week Multicenter Study. Actas Dermo-Sifiliograficas. 2025; 116(7)DOI:10.1016/j.ad.2024.08.014. PMID:. IF:(Q/D).
01/06/2025
Surgical Approach to Hidradenitis Suppurativa
Mateu-Arrom, L, Puig, L, Vilarrasa, E. Surgical Approach to Hidradenitis Suppurativa. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2024.10.061. PMID:40185225. IF:(Q/D).
01/06/2025
Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Smith, A, Armstrong, AW, Elewski, B, Rich, P, Augustin, M, Carrascosa, JM, Vender, R, Lambert, J, Pinto, JML, Hoepken, B, Kavanagh, S, Puig, L. Bimekizumab clinical efficacy in impactful body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2025; 66DOI:. PMID:. IF:1.800(Q3/6D).
01/04/2025
Real-world Efficacy of Brodalumab in Patients with moderate to severe Plaque Psoriasis, in Patients with BMI>30 and BMI=30, BROACTIVE: 2-year Results
Escalas, J, Armesto, S, Abalde, T, Blanco, IR, Blanco, MR, Herrera-Acosta, E, Puig, L, Morales, AM, Ferrán-Farrés, M, Auhage, E, Ribera, M. Real-world Efficacy of Brodalumab in Patients with moderate to severe Plaque Psoriasis, in Patients with BMI>30 and BMI=30, BROACTIVE: 2-year Results. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2025; 23DOI:. PMID:. IF:3.800(Q1/2D).
01/04/2025
Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis
Thaçi, D, Puig, L, Papp, K, Gold, LS, Fernández-Peñas, P, Huang, YH, Dossenbach, M, Falques, M, Agell, H, Schönherr, F, Vestergaard, C. Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2025; 23DOI:. PMID:. IF:3.800(Q1/2D).
01/01/2025
EFFECTIVENESS OF 12-MONTHS TRALOKINUMAB TREATMENT IN 124 ADULTS WITH ATOPIC DERMATITIS WITH GENITAL INVOLVEMENT: FINAL REAL-WORLD DATA FROM THE PROSPECTIVE, NON-INTERVENTIONAL, INTERNATIONAL, SINGLE-COHORT TRACE STUDY
Ameen, A, Serra-Baldrich, E, Arm-Strong, A, Festini, T, Vinther, F, Vittrup, I, Wiseman, MC. EFFECTIVENESS OF 12-MONTHS TRALOKINUMAB TREATMENT IN 124 ADULTS WITH ATOPIC DERMATITIS WITH GENITAL INVOLVEMENT: FINAL REAL-WORLD DATA FROM THE PROSPECTIVE, NON-INTERVENTIONAL, INTERNATIONAL, SINGLE-COHORT TRACE STUDY. ACTA DERMATO-VENEREOLOGICA. 2025; 105DOI:. PMID:. IF:3.700(Q1/2D).
12/01/2024
Student survey after ten years of continuous blended teaching of echocardiography.
Parra VM, Fita G, Azqueta M, González M, Aranda F, Maestre M, Silva J, Hortal J, Morales D, Bórquez E, Adasme F, Real MI, Mercadal J, Zelada P, Riobó G, Galdames K, Domenech RJ. Student survey after ten years of continuous blended teaching of echocardiography.. Revista Espanola De Anestesiologia Y Reanimacion. 2024; 71(1)DOI:10.1016/j.redare.2023.05.004. PMID:37683971. IF:(Q/D).